TheraRadar

Pharma Intelligence, Simplified

Data updated: Mar 10, 2026

TECHNIVIE

OMBITASVIR
Approved 2015-07-24
2
Indications
--
Phase 3 Trials
1
Priority Reviews
10
Years on Market

Details

Status
Discontinued
First Approved
2015-07-24
Routes
ORAL
Dosage Forms
TABLET

Companies

Active Ingredient: OMBITASVIR , PARITAPREVIR , RITONAVIR

TECHNIVIE Approval History

Loading approval history...

What TECHNIVIE Treats

2 FDA approvals

Originally approved for its first indication in 2015 . Covers 2 distinct patient populations.

  • Other (2)
🔬

Active Pipeline

Pro

Ongoing clinical trials by development phase

Loading...

Key Completed Trials

Pro

Completed studies with published results, ranked by significance

Loading...
📊

Trial Timeline

Full development history with FDA approval milestones

Loading...
Understanding FDA Approval Types
Count Type What it means
- ORIG Original approval - drug first enters market
- SUPPL - Efficacy New indication (new disease/condition approved)
- SUPPL - Labeling Label text changes (warnings, dosing updates)
- SUPPL - Manufacturing Production changes (new facility)
- SUPPL - Chemistry Formulation changes (new dosage strength)

Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.

TECHNIVIE FDA Label Details

Pro

TECHNIVIE Patents & Exclusivity

Latest Patent: Apr 2032

Patents (7 active)

US8691938 Expires Apr 13, 2032
US8420596*PED Expires Oct 10, 2031
US8686026 Expires Jun 9, 2031
US9044480 Expires Apr 10, 2031
US8420596 Expires Apr 10, 2031
US9006387 Expires Jun 10, 2030
US8642538 Expires Sep 10, 2029
Source: FDA Orange Book

Want competitive intelligence?

See who's developing similar drugs and track their progress

View Pipeline Dashboard

Data Sources

Data sourced from official FDA and NIH databases. Click links to verify on original sources.